Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Innovent Biologics Expands its Antibody Pipeline and Manufacturing Capabilities

Published: Monday, November 19, 2012
Last Updated: Sunday, November 18, 2012
Bookmark and Share
Company raises $25 million in a Series B financing.

Innovent Biologics, Inc. has raised $25 Million in a Series B financing to put toward the continued expansion of its pipeline and manufacturing capabilities.

The money comes from Lilly Asia Ventures, part of the innovative global pharmaceutical company Eli Lilly, and from Fidelity Biosciences and Fidelity Growth Partners Asia, a division of Fidelity, one of the world's leading financial services companies. Fidelity is a follow-on investor from the Series A.

"We are fortunate to have world's premier investors believing in our team and business. Biologics are going to be a huge category in China just as they are worldwide, which presents a unique, once in a lifetime opportunity. Innovent has positioned itself to be a leading biologics company in China", Said Michael Yu, Ph.D., Co-founder, President and CEO of Innovent Biologics.

The team at Innovent brings extensive experience in the discovery, development and manufacture of biologics in the US, Europe and worldwide and were involved in the launch of such products as Bexxar, Conbercept, Humira, Natrecor, Oncorine, Orencia, and others.

Innovent has a GMP-compliant pilot plant for the production of clinical trial material and is building a new campus located in Suzhou near Shanghai China.

In addition to laboratories and offices, the campus will house a commercial manufacturing plant with multiple 12,000 L bioreactors and a pilot plant, with two 1000L bioreactors, for production of clinical materials.

The 90,000m2 biopharmaceutical facility will be the largest biologics production facility in China designed to comply with international requirements for cGMP as defined by the European EMA and the US FDA, as well as meet China SFDA cGMP regulations.

Companies who want to leverage the Innovent commitment to bring quality manufacturing and development to the expanding China biologics market have helped Innovent begin building a pipeline of biologics.

The pipeline currently includes a CD20 antibody for Non-Hodgkins Lymphoma (NHL) and other B cell mediated diseases, a bispecific antibody for cancer and an antibody for oncology.

Innovent continues to actively seek product candidates for in-licensing and co-development.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,200+ scientific posters on ePosters
  • More Than 4,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
Open Source Seed Initiative – A Welcome Boost to Global Crop Breeding
A team of plant breeders, farmers, non-profit agencies, seed advocates, and policymakers have created the Open Source Seed Initiative.
ASMS 2016: Targeting Mass Spectrometry Tools for the Masses
The expanding application range of MS in life sciences, food, energy, and health sciences research was highlighted at this year's ASMS meeting in San Antonio, Texas.
A New Way Out for Stem Cells
Researchers at North Carolina State University have discovered that therapeutic stem cells exit the bloodstream in a different manner than was previously thought.
One Giant Leap for the Future of Safe Drug Delivery
Sheffield engineers make major breakthrough in developing silk ‘micro-rockets’ that can be used safely in biological environments.
Designing Potential AIDS Vaccine Candidates
Findings represent ‘big accomplishment’ in biomedical engineering and design.
Anticancer Drug Stops Ebola Virus Molecule in its Tracks
A team of scientists from the University of Oxford have successfully mapped the structure of the Ebola virus molecule that drives the attack strategy and leads to fatal infections in humans.
Assessing the Effectiveness of Genome-Editing Technologies
Researchers have developed a cost-effective and rapid method for assessing edits generated by CRISPR-Cas9 and other genome-editing technologies.
Anthrax Proteins Might Help Treat Cancerous Tumors
Studies in mice reveal novel treatment regimen.
New Cancer Drug Target Found in Dual-Function Protein
Findings from a study from TSRI have shown that targeting a protein called GlyRS might help to halt cancer growth.
Key to Chronic Fatigue Syndrome is in Your Gut, Not Head
Researchers report they have identified biological markers of the disease in gut bacteria and inflammatory microbial agents in the blood.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,200+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!